ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020
Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR).
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- An interpretable machine learning model based on CT imaging for predicting lymphovascular invasion and survival in bladder urothelial carcinoma: a multicenter study.BMC medical imaging · 2025Article
- Deep learning feature-based model for predicting lymphovascular invasion in urothelial carcinoma of bladder using CT images.Insights into imaging · 2025Article
- 2025 Canadian Urological Association Expert Report: Muscle-invasive bladder cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance.Urologic oncology · 2024Review
- Oxidative Stress Markers in Urine and Serum of Patients with Bladder Cancer.Antioxidants (Basel, Switzerland) · 2023Article
- Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective.Frontiers in oncology · 2023Review
- T1 bladder carcinoma with variant histology: pathological features and clinical significance.Virchows Archiv : an international journal of pathology · 2022Article
- Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies.World journal of urology · 2022Review
- The 2022 ENCR Recommendations on recording and reporting of urothelial tumours of the urinary tract.Frontiers in oncology · 2022Article
- Review
- Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.Frontiers in surgery · 2021Review
- Under-reporting of carcinoma in situ in patients with high-grade papillary non-muscle-invasive bladder cancer.Bladder cancer (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The International Collaboration on Cancer Reporting (ICCR) is an alliance of major pathology organisations in Australasia, Canada, Europe, United Kingdom, and United States of America that develops internationally standardised, evidence-based datasets for the pathology reporting of cancer specimens. This dataset was developed by a multidisciplinary panel of international experts based on previously published ICCR guidelines for the production of cancer datasets. It is composed of Required (core) and Recommended (noncore) elements identified on the basis of literature review and expert consensus. The document also includes an explanatory commentary explaining the rationale behind the categorization of individual data items and provides guidance on how these should be collected and reported. The dataset includes nine required and six recommended elements for the reporting of cancers of the urinary tract in biopsy and transurethral resection (TUR) specimens. The required elements include specimen site, operative procedure, histological tumor type, subtype/variant of urothelial carcinoma, tumor grade, extent of invasion, status of muscularis propria, noninvasive carcinoma, and lymphovascular invasion (LVI). The recommended elements include clinical information, block identification key, extent of T1 disease, associated epithelial lesions, coexistent pathology, and ancillary studies. The dataset provides a structured template for globally harmonized collection of pathology data required for management of patients diagnosed with cancer of the urinary tract in biopsy and TUR specimens. It is expected that this will facilitate international collaboration, reduce duplication of effort in updating current national/institutional datasets, and be particularly useful for countries that have not developed their own datasets.
Indexed as
Identifiers
31685965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.